BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38060043)

  • 1. 1% Tapinarof cream for the treatment of psoriasis: a network meta-analysis of randomized placebo- and calcipotriol- controlled trials.
    Yan J; Chen S; Shi J
    Arch Dermatol Res; 2023 Dec; 316(1):31. PubMed ID: 38060043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
    N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
    Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
    Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
    J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S2-S14. PubMed ID: 38014659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VTAMA
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2022; 20(4):298-300. PubMed ID: 35976021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S1-S13. PubMed ID: 38051146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
    Desai SR; Stein Gold L; Cameron MC; Golant A; Lewitt GM; Bruno MJ; Martin G; Brown PM; Rubenstein DS; Butners V; Tallman AM
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2443-2460. PubMed ID: 37697121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
    Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
    J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis.
    Grossmann MC; Pixley JN; Feldman SR
    Ann Pharmacother; 2024 Jan; 58(1):76-85. PubMed ID: 37076998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
    Jett JE; McLaughlin M; Lee MS; Parish LC; DuBois J; Raoof TJ; Tabolt G; Wilson T; Somerville MC; DellaMaestra W; Piscitelli SC
    Am J Clin Dermatol; 2022 Jan; 23(1):83-91. PubMed ID: 34713415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
    van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
    Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults.
    Kalabalik-Hoganson J; Nogid A; Frey K
    J Drugs Dermatol; 2023 Aug; 22(8):761-765. PubMed ID: 37556516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
    Strober B; Stein Gold L; Bissonnette R; Armstrong AW; Kircik L; Tyring SK; Piscitelli SC; Brown PM; Rubenstein DS; Tallman AM; Lebwohl MG
    J Am Acad Dermatol; 2022 Oct; 87(4):800-806. PubMed ID: 35772599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of using calcipotriol-betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis.
    Ren J; Zhu Q; Wang S; Li X; Sun Z; Li N; Feng J; Ding H; Dong S; Wang H
    Arch Dermatol Res; 2022 Sep; 314(7):633-641. PubMed ID: 34417633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
    Pinter A; Reich A; Arenberger P; Gold LS; Armstrong A; Iversen L; Praestegaard M; Augustin M
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2327-2335. PubMed ID: 37432045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris.
    Holmback J; Carlsson A; Rinwa P
    J Drugs Dermatol; 2023 Feb; 22(2):197-202. PubMed ID: 36745360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.